Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685 91. 18. Lewis EF, Claggett BL, McMurray JJV, et al. Health- related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10:e003430. 19. Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol. 2019;108:1074 82. 20. Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection frac- tion: a randomized clinical trial. JAMA. 2019;322:1 10. 21. Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18: 1193 202. 22. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74:1966 2011. 23. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decom- pensated heart failure. N Engl J Med. 2019;380:539 48. 24. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSI- TION study. Eur J Heart Fail. 2019;21:998 1007. 25. Mann DL, Greene SJ, Givertz MM, et al. Sacubitril/ valsartan in advanced heart failure with reduced ejec- tion fraction: rationale and design of the LIFE Trial. J Am Coll Cardiol HF. 2020;8:789 99. 26. Velazquez EJ, Morrow DA, DeVore AD, et al. 